Hormone Therapy with Chemotherapy May Prolong Survival from Prostate Cancer
Results from a study presented at the American Society of Clinical Oncology annual meeting found that by combining two types of treatment, men suffering from advanced prostate cancer may live longer. Hormone-depleting therapy has been a standard treatment for decades. It’s usually effective until the cancer progresses to a point that it’s resistant to the therapy.
This is generally when chemotherapy treatment begins with a drug called docetaxel. But a new study finds that adding this drug with hormone-depleting therapy could extend the patient’s life.
The researchers divided 790 men (with a recent diagnosis of advanced hormone-sensitive prostate cancer) into two groups. For 18 weeks, one group underwent hormone therapy. The other received the chemotherapy drug plus hormone therapy.
The researchers found the median survival rate for those who received just hormone therapy was 44 months. In comparison, it was 57.6 months for those who underwent both types of treatment.
Researchers also looked at cases where the cancer had spread to major bones or organs. The median survival rate for those who underwent hormone therapy alone was 32.2 months. And it was 49.2 months for those who received hormone therapy plus docetaxel.
Finally, they considered the impact of treatment on the cancer’s progression. The median time to progression was 19.8 months after getting treated solely with hormone therapy. This is where the biggest difference occurred. The median time to progression was 32.7 months after receiving both types of treatment.
Those who receive a diagnosis of prostate cancer might also qualify for Social Security disability benefits. This can help significantly with the financial burden created when the cancer prevents the individual from continuing to work. To learn more about eligibility, contact the Disability Help Group at 1-(800)-800-3332.